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Abstract
Background: Specialist palliative care (SPC) interventions aim to relieve and prevent suffering in the physical,
psychological, social, and spiritual domain. Therefore, SPC is carried out by a multi-professional team with different
occupations (e.g., physician, nurse, psychologist, and social worker). Remaining skepticism concerning the need for SPC
may be based on the scarcity of high-quality evaluations about the external evidence for SPC. Therefore, we will conduct
a systematic review according to Cochrane standards to examine the effects of SPC for adults with advanced illness.
Methods/design: The comprehensive systematic literature search will include randomized controlled trials (RCTs) and
cluster RCTs. We will search the databases MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL),
and PsycINFO.
Patients must be adults suffering from life-limiting diseases. Proxy and caregiver outcomes will not be assessed in order to
ensure a clear and well-defined research question for this review. Interventions may be in an in- or outpatient setting, e.g.,
consulting service, palliative care ward, and palliative outpatient clinic. In line with the multi-dimensional scope of
palliative care, the primary outcome is quality of life (QoL). Key secondary outcomes are patients’ symptom burden,
place of death and survival, and health economic aspects. Subgroup analysis will assess results according to cancer
type, age, early vs not early SPC, site of care, and setting.
Analysis will be performed with the current RevMan software. We will use the Cochrane Collaboration risk of bias
assessment tool. The quality of evidence will be judged according to the Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) approach.
Discussion: The available evidence will be summarized and discussed to provide a basis for decision-making among
health care professionals and policy makers. For SPC, we believe that multi-professional care is of utmost importance.
Therefore, single-profession interventions such as physician consultations will not be included. Based on the multi-
dimensional scope of palliative care, we chose QoL as the primary outcome, despite an expected heterogeneity
among the QoL outcomes. We consider unidimensional endpoints such as “pain” for the physical domain to be
inadequate for capturing the true scope of (S)PC (i.e., QoL) as defined by the World Health Organization.
Systematic review registration: PROSPERO CRD42015020674
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Background
Palliative care aims to relieve and prevent suffering in
the physical, psychological, social, and spiritual do-
main [1] for people with advanced and life-limiting
diseases. Palliative care has often been misconstrued
as terminal or end-of-life care or as the provision of
disease-modifying interventions for incurably ill pa-
tients [2, 3]. Therefore, it is important to prevent
such misunderstandings in the interpretation of
research publications by referring to an existing defin-
ition for palliative care when outlining the scope of
research [2, 3]. For this review, the definition of the
World Health Organization (WHO) provides a com-
mon basis [1].
It is important to point out that the WHO defines
palliative care as an approach that is delivered by all
physicians (regardless of their discipline) caring for a
patient (i.e., general, primary, or basic palliative care)
[1, 3]. Beyond this, the WHO also supports the de-
velopment and widespread availability of specialist
palliative care (SPC) or speciality palliative care.
Normally, SPC is provided by multi-professional
teams on inpatient wards or as consultation teams
within hospitals in outpatient clinics and as palliative
home care. [4]. Recently, SPC has become increas-
ingly available. For example, palliative care consult-
ation services/teams (i.e., mostly consisting of a
physician, an experienced nurse, a psychologist, and
a social worker) are being rapidly implemented,
especially in large academic centers [5]. In the USA,
the proportion of academic medical centers provid-
ing a palliative care consultation service has in-
creased fivefold (from 15 to 75 %) during the last
decade [5]. In contrast, the provision of inpatient
palliative care wards is not very well-established in
the USA, though there is a comparatively long trad-
ition in Western Europe [6].
Description of the condition
Palliative care aims at improving “quality of life of pa-
tients and their families facing the problems associated
with life-threatening illness, through the prevention
and relief of suffering by means of early identification
and impeccable assessment and treatment of pain and
other problems, physical, psychosocial, and spiritual”
[7]. Among patients with (advanced) cancer, common
physical (e.g., nausea) and psychosocial (e.g., depres-
sion, anxiety) needs as well as economic concerns are
not adequately addressed [8]. In addition, hospital
staff often reports not having enough time to care for
dying patients and the majority does not feel well-
prepared for this task according to a representative
survey [9]. Moreover, intensive or aggressive therapies
at the end of life (e.g., chemotherapy) have a considerable
financial impact on patients/patient’s family and soci-
ety [10]. Aggressive therapies at the end of life might
not even be beneficial for patients’ quality of life
(QoL) [10, 11].
Why it is important to do this review
Even when SPC services are available, some physi-
cians hesitate to initiate a specialist palliative care
visit for their patients [12–15]. The scarcity of high-
quality evaluations (e.g., systematic reviews) about the
effectiveness of SPC could be one reason for this
[15]. In fact, there is an unclear evidence base for
most of the recommendations for the integration of
SPC [16]. To bridge this gap, it is crucial to assess
the evidence base of SPC and identify the most
effective components of SPC [17–19].
To more adequately address the unmet needs of pal-
liative care patients, the availability of SPC in addition
to basic (or general) palliative care [1, 3] is being in-
creasingly advocated [3, 4, 13, 20]. SPC has also
emerged as a medical specialty and is available in
addition to general palliative care in many different set-
tings [20–22]. Currently, the integration of SPC into
the care of patients with various advanced and incur-
able illnesses (e.g. cancer, heart failure, neurodegenera-
tive diseases) is recommended [3, 16, 23–26]. The
integration of SPC is said to increase patients’ QoL,
reduce patient and family distress and the aggressive-
ness of care and health care costs, and may even pro-
long life [3, 27, 28].
We used the Preferred Reporting Items for Systematic
review and Meta-Analysis Protocols (PRISMA-P) 2015
checklist in order to ensure completeness of the protocol
(Additional file 1). The primary objective of this system-
atic review is to examine the effects of SPC services for
adults with advanced illness on QoL.
Methods/design
Criteria for considering studies for this review
Types of studies
According to the Cochrane Handbook [29] and based
on the availability of RCTs found by comparable reviews
[3, 30], we chose to include the following types of
studies:
1. Double-, single-blind, or not blinded RCTs
2. Cluster RCTs
We decided to exclude all other study designs because
none of the three main reasons for including non-
randomized studies stated in the Cochrane Handbook
(chapter 13.1.2) were applicable [29].
We will include full journal publications, results from
clinical trial platforms (if not stated in journals), and
Gaertner et al. Systematic Reviews  (2015) 4:123 Page 2 of 9
abstracts with sufficient data for analysis of otherwise
unpublished clinical trials.
We define “randomized” as studies that are de-
scribed by the authors as “randomized” anywhere in
the manuscript, except in cases where the term is
misused (e.g., referring to a random sample).
Types of participants
Adult in- or outpatients (aged 18 years or older) with
advanced illness, regardless of whether malignant or non-
malignant (e.g., metastatic lung cancer, glioblastoma, heart
or renal failure, neurodegenerative diseases, etc.), who are
receiving SPC (as described below) were included. “Ad-
vanced illness is defined as when one or more conditions
become serious enough that general health and function-
ing decline and treatment begins to lose effect – a process
that extends to the end of life” [31].
Description of the intervention
SPC (synonyms: specialized or specialty palliative care)
Normally, SPC is provided by multi-professional
teams on inpatient wards or by consultation teams
within hospitals, in outpatient clinics, and as palliative
home care [4].
How the intervention might work
SPC services are provided by health care professionals
who usually have received a higher degree of palliative
care training. Another advantage of SPC services is that
they can focus on alleviating and preventing suffering
without being primarily responsible for the disease-
modifying therapies (e.g., chemotherapy, cardiovascular
interventions) [16, 23–26]. Also, if such conjoint and
interdisciplinary cooperation of the primarily responsible
disciplines (e.g., cardiology, oncology, or neurology) with
SPC services is well coordinated, the joining of the ex-
pertise, vigilance, and workforce of both disciplines may
improve efficacy and safety of care. These aspects along
with the multi-professional care model allow SPC teams
to cover a broad range of the different domains of suffer-
ing (physical, psychological, social, and spiritual) [1, 3,
11, 30, 32]. Moreover, there is some evidence that SPC
may have economic benefits without reducing quality of
life [33, 34].
Types of interventions
Definition of SPC and usual care
In this review, we will evaluate SPC services. We de-
fine SPC as described by Zimmermann et al.: “A spe-
cialized palliative care service was defined as a service
of health care professionals from at least two different
professions that provides or coordinates comprehen-
sive care for patients with an [advanced illness]. Stud-
ies evaluating the impact of only 1 component of
comprehensive palliative care on only 1 aspect of
quality of life (eg, impact of pain medication on pain;
impact of medication or psychotherapy on depression)
will be excluded” [30]. Subsequently, we will use the
criteria developed by Gomes et al. [30] to analyze the
different SPC interventions of the included studies.
SPC will be compared with usual care. We define
usual care as care which is provided by personnel
that are not designated as SPC professionals.
Site of care
We will evaluate SPC services in (i) hospitals (i.e., pallia-
tive care inpatient ward or hospital consulting services),
(ii) hospices, or (iii) community settings.
Direct patient care
Services and interventions not directly delivering
care to patients will not be included. This concerns
education or training programs for health profes-
sionals as well as interventions limited to providing
staff advice or offering service coordination. More-
over, interventions solely providing assessments (e.g.,
screening tool) or the implementation of new policies/
algorithms and (e.g., national) strategies will not be
included.
Types of outcome measures
Primary outcome
– Patients’ QoL assessed with validated and non-
validated questionnaires or single-items
Secondary outcomes
– Psychosocial variables: distress, depression, anxiety,
spiritual well-being, social well-being, and satisfaction
with care as reported by the patient and/or a proxy
and assessed with validated and non-validated
questionnaires or single-items
– Pain, fatigue, nausea, and dyspnea as reported by the
patient and/or a proxy and assessed with validated
and non-validated questionnaires or single-items
– Survival time
– Place of death (hospital, hospice, community setting,
home, others)
– Cost of care (direct and indirect costs)
– Attrition number and reasons
– Adverse events
We will exclude studies that focus on outcomes
other than those stated. Outcomes will be analyzed at
the point in time of the primary outcome (except for
the outcome place of death). Psychosocial variables
and symptoms may differ whether they are reported
Gaertner et al. Systematic Reviews  (2015) 4:123 Page 3 of 9
directly by the patient or indirectly by a proxy.
Therefore, they will be considered as two separate
types of outcomes (e.g., constipation: patient-reported
or proxy-reported).
Search methods for identification of studies
Electronic searches
We will conduct searches using the databases MEDLINE
(via Ovid), EMBASE (via DIMDI), Cochrane Central
Register of Controlled Trials (CENTRAL), and Psy-
cINFO (via EBSCO).
The search strategy that we will use to search
MEDLINE can be found in Appendix 1. We will
modify the search strategy where necessary to search
the other databases listed. No date or language re-
strictions will be applied.
We applied the RCT sensitivity-maximizing search
strategy provided by Cochrane [35] and parts of the BMJ
search strategy for RCTs [36].
Searching other resources
Textbooks and trial registers
We will hand-search the reference lists of the following
three textbooks:
– Textbook of Palliative Medicine [37]
– Oxford Textbook of Palliative Medicine [38]
– Oxford Textbook of Palliative Nursing [39]
We will identify ongoing trials via (i) the metaRegister
of controlled trials (http://www.controlled-trials.com/),
(ii) clinicaltrials.gov (www.clinicaltrials.gov), and (iii) the
WHO International Clinical Trails Registry Platform
(ICTRP; http://apps.who.int/trialsearch/).
Reviews
We will identify relevant reviews and will hand-search
the reference lists.
Correspondence
We will contact authors of the main studies and inves-
tigators who are known to be carrying out research
about SPC and authors of relevant textbook sections
and reviews for further studies and unpublished data.
These will include at least (alphabetical order): Amy
Abernethy, Susan Block, Andrew Billings, Eduardo
Bruera, Stein Casa, David Currow, Barbara Gomes,
Irene Higginson, John Lynch, Thomas J. Smith, Jennifer
Temel, and Declan Walsh.
Conference proceedings and other
We will hand-search conference proceedings of the
Congress of the European Association for Palliative
Care (EAPC) 2013, 2014 and 2015.
Data collection and analysis
Selection of studies
One review author (WS) will screen the titles and
abstracts to remove duplicates. Two reviewers (JG, WS)
will screen titles and abstracts for relevance and judge
the eligibility of the studies. We will resolve disagree-
ments by consensus and with a third review author
(GB). Multiple reports of studies will be linked together.
Uncertainties concerning multiple reporting will be
resolved by contacting authors.
We will include a Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) flow
chart [40] in the full review that will show the status of
identified studies as recommended in the Cochrane
Handbook [41].
Data extraction and management
We will enter data from each selected study into a data
extraction form. Two reviewers (JG, WS) will independ-
ently extract data for each study. We will resolve dis-
agreements by consensus or with a third review author
(GB) when needed. We will contact authors of studies to
provide unpublished data for the meta-analysis, if
required.
Assessment of risk of bias in included studies
Two authors (JG, WS) will independently assess the
risk of bias for each study. We will use the Cochrane
Collaboration’s risk of bias tool and the correspond-
ing criteria for judging risk of bias that are provided
in the Cochrane Handbook [42]. The features of the
Cochrane Collaboration’s risk of bias tool encompass
the following:
– Selection bias: sequence generation and allocation
concealment
– Performance bias: blinding of participants and
personnel
– Detection bias: binding of outcome assessment
– Attrition bias: incomplete outcome data
– Reporting bias: selective outcome reporting
– Other bias: other sources of bias (e.g., not
appropriate study design or contamination)
We will include these risk of bias assessments in the
evaluation of evidence according to the Grading of Rec-
ommendations Assessment, Development, and Evalu-
ation system (GRADE system) [42, 43]. The quality level
concerning QoL (our primary outcome) or the primary
outcome stated in a study will be down- or upgraded if
applicable, according to the Cochrane Handbook [44].
Economic evidence will be assessed using the CHEERS-
checklist [45].
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Measures of treatment effect
The software Review Manager (Cochrane Collabor-
ation) will be used to combine the data from all in-
cluded studies. When sample size and proportions are
missing, they will not be imputed or estimated for
meta-analysis. Instead, we will contact the authors to
acquire additional data. The random-effects model
will be used for meta-analysis, since we anticipate
that study designs and interventions will differ be-
tween studies. The Mantel-Haenszel (default configur-
ation) will be used as the statistical method. If
authors use the same assessment tools, we will evalu-
ate continuous data using the mean difference (MD).
If not, results from the meta-analysis will be shown
using the standardized mean difference (SMD). Re-
sults for dichotomous data will be analyzed by calcu-
lating the risk ratio (RR). We will use the generic
inverse-variance method to analyze survival data be-
cause it can integrate both log-rank and Cox model
estimates. Moreover, the generic inverse-variance
method enables a random-effects analysis whereas the
“O – E and Variance” outcome type does not [41].
Hazard ratios and the corresponding standard errors
will be calculated using methods described in Parmar et
al. (1998) if not reported in publications [46].
To review the cost-saving potential of SPC, the total
(cross-sectoral) cost of care for the SPC service group
and the control group(s) will be retrieved from the
eligible studies (if available) which provide an eco-
nomic evaluation. To allow a consistent economic
comparison, only those studies will be included in
which palliative care is the intervention and in which
cost measures are combined with QoL (i.e., economic
information based on cost studies or cost of illness
studies will not be extracted). Economic data should
comprise hospital costs, other institutional care costs,
community care costs, informal care costs, and equip-
ment and medication prescribed. If only the cost for
the additional SPC service is provided, this informa-
tion will not be extracted. The reason is that this
cannot be viewed as “additional costs” since SPC ser-
vice provision may result in cost-saving effects in
other health care sectors, e.g., due to fewer intensive
or aggressive therapies (i.e., chemotherapy) or other
procedures (e.g., diagnostic (staging) test) at the end
of life [3].
Unit of analysis issues
We expect that the level of randomization may differ
between studies. Individual randomization and cluster
randomization is possible [11, 32]. We will take intra-
cluster correlation (ICC) into account for studies
reporting cluster randomization [32]. If ICC is not
stated, the authors will be contacted. Repeated mea-
surements for the same outcomes may also occur in
trials. We will analyze outcomes at the point in time
that was defined by the authors for the primary out-
come (except for the outcome place of death). Other
issues like individuals undergoing more than one
intervention (e.g., cross-over trial) are extremely un-
likely in the SPC study setting.
Dealing with missing data
We will attempt to contact the trial authors if rele-
vant data (e.g., inadequate flowchart with reasons for
dropouts) are missing. Numbers of screened and ran-
domized patients as well as dropouts will be taken
into account (e.g., sensitivity analysis). We will critic-
ally document whether the intention to treat (ITT) or
per-protocol (PP) approach was used or if and which
imputation methods (e.g., last observation carried for-
ward) were applied. For trials using continuous out-
comes in which standard deviations (SDs) were not
reported and no information is available from the au-
thors, we will calculate the SDs via the standard error
of the mean (SEM).
Assessment of heterogeneity
The statistical heterogeneity will be judged by use of the
chi-square test and I2 statistic [41]. I2 calculates the
percentage of the variability in effect estimates due to
heterogeneity rather than chance. Here, higher percent-
ages suggest more observed heterogeneity with 0–40 %
indicating not being important, 30–60 % representing
moderate, 50–90 % substantial, and 75–100 % consider-
able heterogeneity [41].
Clinical heterogeneity will be assessed by analyzing
results according to cancer type, age, early vs not early
SPC, site of care, and setting (see also “Subgroup ana-
lysis and investigation of heterogeneity” section).
Assessment of reporting biases
Funnel plots of the primary outcome (QoL) will only be
calculated to assess heterogeneity and publication bias
if >10 studies are included in the meta-analysis [41].
We will use contour-enhanced funnel plots in order to
facilitate differentiation between publication bias and
other sources of asymmetry in the funnel plots [41].
Further, we will consider heterogeneity (patients, inter-
ventions, control group, study design) and contextual
factors (e.g., historical or cultural factors) when inter-
preting funnel or forest plots.
In addition, reporting bias and publication bias will be
assessed by checking the trial registers as stated in the
chapter “Textbooks and trial registers.” Authors will be
contacted if necessary (see also the “Correspondence”
section).
Gaertner et al. Systematic Reviews  (2015) 4:123 Page 5 of 9
Data synthesis
Summary of the evidence and quality appraisal for QoL
or the primary outcome stated in a study will be pre-
sented according to the criteria developed by the
GRADE working group [42, 43, 47]. We will generate a
summary of findings table according to the GRADE
system and include QoL (primary outcome) and the
following secondary outcomes that were chosen in a
consensus process and discussion in our research
group: depression, satisfaction with care, pain, survival
time, place of death, and number of patients with at
least one adverse event.
In palliative care, health-related quality of life (HRQol)
encompasses the physical, psychological, social, and
spiritual domain. We will include all measures for QoL
that include items from at least two of the four domains
(physical, psychological, social, or spiritual) in our meta-
analysis.
Data concerning the primary outcome (QoL) will
be assessed using a random-effects model to account
for the heterogeneity in populations and interven-
tions [41]. We will use MDs or SMDs for continu-
ous data and RRs for dichotomous data as effect
estimates.
Statistical and clinical heterogeneity will be addressed
as stated in the chapter “Assessment of heterogeneity”
and “Assessment of reporting biases.”
Subgroup analysis and investigation of heterogeneity
Considering previous studies [3, 18, 30], it is very likely
that the participants, interventions, comparators, and out-
comes will be highly variable (see the “Sensitivity analysis”
section). If these are not judged as similar enough to
ensure a clinically meaningful statement, meta-analysis
will not be undertaken according to the Methodo-
logical Expectations of Cochrane Intervention Reviews
(MECIR) standards [48]. This judgement will be a
joint decision of the whole group. Results will be ana-
lyzed and presented in a descriptive way if no meta-
analysis is performed.
We defined the following subgroups:
(i) Cancer vs non-cancer patients
(ii)Within non-cancer patients: patients with
neurological disease (e.g., amyotrophic lateral
sclerosis (ALS), multiple sclerosis (MS)) vs
chronic-obstructive-pulmonary disease (COPD) vs
heart failure
(iii)Elderly patients vs younger patients (elderly
defined as >79 years of age according to the
Medical Subject Heading (MeSH) “aged” and
based on the clinical experience of the research
group; younger patients are defined as
18–79 years)
(iv) Patients treated early vs not early with SPC
(early defined as: Eastern Cooperative Oncology
Group (ECOG) 0–2 or Karnofsky index 50–100
or 6–24 months estimated survival or initiation
of SPC within 8 weeks after diagnosis of an
advanced incurable illness as defined in the
identified studies)
(v)Site of care: hospitals vs hospices vs community
settings
(vi)Inpatients vs outpatients
We will analyze the subgroups using a random-effects
model [49] and will evaluate the statistical heterogeneity
using the chi-square test and I2 statistic (see the “Assess-
ment of heterogeneity” section). For dichotomous data,
we will use Mantel-Haenszel as statistical method
because it has better statistical properties when there are
few events [41].
If a meta-analysis is performed, the results should
be interpreted with caution. A summary measure for
the subgroups’ mean diamonds (total) will not be cal-
culated if the study variability is too high (e.g., partic-
ipants, interventions, etc.). If a meta-analysis is not
possible, the results of the subgroups will be com-
pared descriptively.
Sensitivity analysis
As described earlier in the protocol, the studies eli-
gible for this review will vary greatly in terms of the
study population (underlying diagnosis, site of care,
stage of the disease), intervention (teams with highly
experienced and trained team members vs teams with
rather unclear staff expertise), comparator (standard
care at a large medical center vs standard care in a
primary care setting), and study design (single-center
vs multi-center studies). Concerning the outcome, no
great variations are expected since most of the studies
of previous reviews include QoL measures [3, 18, 30].
After primary data synthesis, we will identify the best
and worst effect studies and critically judge them
according to the mentioned factors (population, com-
parator, etc.). Assumptions and key issues of this
group discussion will be recorded and reported. If
applicable, sensitivity analysis will be undertaken after
possibly misleading studies have been identified. We
will publish a separate meta-analysis if the results
change significantly after performing the sensitivity
analysis for the mentioned factors (population, inter-
vention, comparator, and study design). This sensitiv-
ity analysis is expected to identify areas for future
research and possible subject-specific sources of bias
that need to be taken into account by researchers
when planning future clinical trials.
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Discussion
Within clinical and academic settings, the palliative
care needs of patients have received increased atten-
tion and recognition, but still, these needs remain un-
met for many patients [3, 8, 28]. Indeed, there is still
a considerable degree of suffering among patients
with advanced, incurable diseases and their families
[16, 21, 23, 25, 26].
One way to improve this situation may be the inte-
gration of SPC teams into the care of patients with
various advanced and incurable illnesses [3, 24, 28].
Landmark studies have reported an increased QoL,
reduced patient and family distress, reduced aggres-
siveness of care and health care costs, and even the
potential to prolong life [3, 27, 28].
To provide high-quality evidence, we have used
Cochrane standards in this protocol. We have prede-
fined how results will be evaluated, how hetero-
geneity will be considered, and how bias will be
assessed.
Most importantly, we will pay close attention to
capturing the specialist aspects and the holistic scope
of palliative care interventions. Therefore, we have
described patients, interventions, comparisons, and
outcomes (PICO) precisely in this protocol. We will
focus on patients with advanced malignant or non-
malignant illness [31]. Caregivers will not be included
as a second population in order to maintain a clear
and well-defined study population and to closely fol-
low the PICO framework [50].
We will use the SPC definition of Zimmermann et al.
[30] because it reflects the multi-professional nature of
the personnel (health care professionals from at least
two different professions), and it assesses multi-
dimensional outcomes in a pragmatic and efficient
way: “Studies evaluating the impact of only 1 compo-
nent of comprehensive palliative care on only 1 aspect
of quality of life (eg, impact of pain medication on
pain; impact of medication or psychotherapy on de-
pression) were excluded” [30].
We chose QoL as our primary outcome. We ac-
knowledge that pain intensity is an important out-
come and has a lower risk of heterogeneity than
QoL. However, SPC interventions should offer a
multi-dimensional approach, according to the defin-
ition of the WHO. For example, interventions pri-
marily aimed at reducing pain (physical domain)
would be considered a part of palliative care but not
palliative care itself. We prefer QoL as our primary
outcome because it captures bio-psycho-social-spirit-
ual aspects and represents the core of palliative care,
despite the fact that no universal understanding of
the concept or even consensus definition of QoL
exists [51]. In palliative care, QoL is usually related
to symptom control, physical function, social func-
tioning, psychological well-being, meaning, and fulfil-
ment (existential and spiritual aspects) and is
referred to as HRQol. Therefore, we decided to in-
clude items from at least two of the four QoL do-
mains (physical, psychological, social, or spiritual) in
our meta-analysis (if applicable).
Evidence from RCTs on this subject will be identi-
fied, and the resulting body of evidence will be
analyzed as described in the methods chapter. Our
results will provide an overview of potential effects
of SPC and may provide a useful basis for decision-
making among health care providers and policy
makers.
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Additional file
Additional file 1: Preferred Reporting Items for Systematic review
and Meta-Analysis Protocols (PRISMA-P) 2015 checklist: recommended
items to address in a systematic review protocol.
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